AVGO vs XENE Stock Comparison

AVGO currently leads XENE in this stock comparison, with AIQ scores of 52 vs 49. The clearest difference is momentum.

Market data as of Nov 15, 2026 market close· AIQ score gap 3 points
AVGO
Technology
vs
XENE
Healthcare
AVGO
Broadcom Inc.
Leads
Price
$347
Day move
-4.76%
AIQ Score
52/100
Best edge
Momentum
Sector
Technology
XENE
Xenon Pharmaceuticals Inc.
Price
$40.48
Day move
-1.26%
AIQ Score
49/100
Best edge
Balanced
Sector
Healthcare

What is the main difference between AVGO and XENE?

AVGO leads the current stock comparison as Broadcom Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Broadcom Inc. vs Xenon Pharmaceuticals Inc.

Data as of Nov 15, 2026· market close· Cross-sector · Technology vs Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

AVGO leads

AVGO leads by 3 AIQ points, primarily on Momentum, but the lead has narrowed from 9 points over 30 sessions. Wall Street currently favors XENE on target upside.

Fragile: 2 of 5 evidence groups support AVGO, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 2 of 5Comparison trend: Weakening
AVGO

Broadcom Inc.

Leads
AIQ Score
52/100
AIQ Edge Score
7/10
XENE

Xenon Pharmaceuticals Inc.

AIQ Score
49/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors AVGO over XENE, 52 versus 49 as of Nov 15, 2026. AVGO's advantage is driven primarily by stronger momentum. AVGO also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors XENE. 2 of 5 covered evidence groups favor AVGO today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. AVGO lead: Weakening — the AIQ differential moved from 9 to 3 points over 30 sessions.

Compare Broadcom Inc. and Xenon Pharmaceuticals Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

AVGO
+565.5%
XENE
+32.2%

Total return comparison

Growth of $10,000, distributions reinvested

AVGO $66,548 · XENE $13,216

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare AVGO and XENE against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

AVGO advantage
0
XENE advantage
  • Momentum40 vs 33
    AVGO +7
  • Risk Resilience47 vs 49
    Even
  • Quality69 vs 68
    Even

2 of 5 evidence groups favor AVGO. AVGO’s edge is concentrated in momentum.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

AVGO0 AIQ

Largest factor move: Momentum -2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 6 active signals are unchanged.

XENE0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

AVGO's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — AVGO and XENE both carry a full feed there.

The central trade-off

AVGO (Broadcom Inc.): the stronger current systematic profile, led by momentum.

XENE (Xenon Pharmaceuticals Inc.): the counter-case, on analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

AVGO

AVGO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

AVGO

AVGO on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

AVGO

AVGO on the Momentum factor, by 7 points.

Lower downside

XENE

XENE carries the lower 1-month annualized volatility.

Analyst upside

XENE

XENE on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors AVGO, analyst targets favor XENE. That disagreement is the most useful thing on this page.

MeasureAVGOXENENote
Implied upside to target+48.5%+67.6%XENE has more room
Target dispersion+48.5%+64.8%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering5118Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 5 covered evidence groups favor AVGO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreEven52 vs 49
FundamentalsAVGOTTM ROE 13.1% vs -9.6%
ValuationNot coveredNot covered
TechnicalsAVGOPrice vs 50-day 0.5% vs -1.6%; vs 200-day -5.6% vs -22.6%
Risk ResilienceEvenRisk Resilience 47 vs 49
Analyst expectationsXENETarget upside 48.5% vs 67.6%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AVGO and XENE and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
  • Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AVGO.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

AVGO lead: Weakening — the AIQ differential moved from 9 to 3 points over 30 sessions.

May 27AVGO leads above the line · XENE leads belowNov 13
Today
AVGO +3
52 vs 49
7 sessions ago
AVGO +1
50 vs 49
30 sessions ago
AVGO +9
55 vs 46
90 sessions ago
XENE +14
59 vs 73

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

AVGOConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only AVGO

  • Accumulation Pattern — bullish, volume, medium horizon (1.18x)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
XENE

0 bullish / 3 bearish / 2 neutral

Only XENE

  • Downtrend Structure Active — bearish, trend, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

Both carry 3 more signals that do not separate them: Death Cross Active, ADX Trend Weakening, ATR Expansion - Breakout Mode.

AVGO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

AVGONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -4.76%, AIQ 0 points).

XENENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1XENE closes the Momentum gap — currently 7 points behind, the largest single contributor to AVGO's edge.
  2. 2XENE's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3AVGO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 3-point move would eliminate AVGO's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

AVGO leads on balance
MetricAVGOXENE
Revenue growth (YoY)33.4%0%
EPS growth (YoY)40.3%0%
Gross margin68.8%0%
Operating margin48.4%0%
Return on equity (TTM)13.1%-9.6%
Debt to equity0.60.01

Performance

AVGO leads 4 of 6 windows
MetricAVGOXENE
1 week (5 sessions)18.2%3.3%
1 month (20 sessions)5.6%20.9%
3 months (63 sessions)-11.6%-35.1%
6 months (126 sessions)-18.4%-25.6%
Year to date0.3%-9.7%
1 year (252 sessions)-2.3%2%

Technicals

AVGO has the stronger structure
MetricAVGOXENE
RSI (14)53.254.9
ADX (14)2324
Price vs 50-day0.5%-1.6%
Price vs 200-day-5.6%-22.6%
Volatility (1M, annualized)70%38%

Risk

Split
MetricAVGOXENE
Beta2.210.86
Sharpe ratio0.210.27
Sortino ratio0.290.48
Max drawdown-39.5%-52.8%
Current drawdown-27.9%-43%
Annualized volatility48.6%68.1%
Value at risk (95%)-4.6%-3.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, AVGO or XENE?

On the Algovestiq AIQ Score, AVGO is the stronger of the two as of Nov 15, 2026, scoring 52 against XENE's 49. The edge comes from momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is AVGO or XENE the better buy right now?

AVGO carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.

Why does the AIQ Score favor AVGO over XENE?

The composite weights Quality, Value, Momentum and Risk Resilience. AVGO leads Momentum by 7 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, AVGO or XENE?

Analyst price targets imply +48.5% upside for AVGO and +67.6% for XENE, so the Street currently favors XENE. That points the opposite way to the AIQ Score, which favors AVGO. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, AVGO or XENE?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, AVGO or XENE?

AVGO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, AVGO or XENE?

AVGO on the Momentum factor, by 7 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, AVGO or XENE?

XENE is the more resilient of the two, so the other name carries the higher downside risk. XENE carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is AVGO more profitable than XENE?

AVGO leads on the comparable margin measures — gross margin 68.8% vs 0%; operating margin 48.4% vs 0%; ttm roe 13.1% vs -9.6%.

Is AVGO's lead over XENE getting stronger or weaker?

AVGO lead: Weakening — the AIQ differential moved from 9 to 3 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the AVGO vs XENE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XENE closes the Momentum gap — currently 7 points behind, the largest single contributor to AVGO's edge; XENE's Death Cross Active resolves — a bearish trend rule currently active against it; AVGO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 3-point move would eliminate AVGO's advantage entirely.

What do the current signals say about AVGO and XENE?

AVGO: 2 bullish / 2 bearish / 2 neutral, conflicted. XENE: 0 bullish / 3 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVGO is Death Cross Active (bearish, long horizon). On XENE it is Death Cross Active (bearish, long horizon).

Compare AVGO and XENE with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.